-
Mashup Score: 48
Surgery remains the standard for lymph-node (LN) metastatic penile cancer. Surveillance or delayed LN dissection (LND) risks missing a curative opportunity. Minimally invasive techniques seem to be feasible and may reduce wound related complications. (Neo)adjuvant treatment has no proven benefit in pN1 disease. More advanced disease is rarely cured by surgery alone and multimodal treatment should be considered after multidisciplinary team discussion. Further prospective and randomised trials on minimally invasive LND, multimodal/novel systemic therapies, and management of recurrent LN are needed.
Source: www.europeanurology.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 2
Endoscopic enucleation of the prostate (EEP) has gained acceptance as an equitable alternative to transurethral resection of the prostate for benign p…
Source: www.sciencedirect.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1October 2023 | European Urology highlights - 5 month(s) ago
Another huge month in European Urology and we bring you selected highlights here on the European Urology podcast. Co-hosts Professor Declan Murphy (Melbourne…
Source: www.youtube.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 2Wise Prostate-specific Antigen Testing Means a Limited, Risk-adjusted, and Personal Approach - 6 month(s) ago
The European Randomized Study of Screening for Prostate Cancer (ERSPC), the only sufficiently powered trial, showed, besides a 20% reduction in prostate cancer mortality in the intervention arm, that many men needed to be screened and to be treated to avoid one prostate cancer death [1]. Since that publication, it has been stated many times that prostate cancer screening can be performed more efficiently and should lead to less overdiagnosis than was initially designed. An early stopping age and limiting the number of tests to three or four are (cost-)effective ways to improve the balance between harms and benefits [2].
Source: www.europeanurology.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 13Neuroendocrine Differentiation in Prostate Cancer: Implications for New Treatment Modalities - 6 month(s) ago
This review aims to provide practising clinicians with the most recent knowledge of the biological nature of prostate cancer (PC) to facilitate investigation of new treatment modalities for patients with PC, especially the hormone-refractory state of the disease.
Source: www.europeanurology.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 1Obesity and Prostate Cancer: A Role for Adipokines - 6 month(s) ago
Obesity and its metabolic sequelae are risk factors for prostate cancer progression. Obesity results in altered secretion of adipokines (leptin, adiponectin, vascular endothelial growth factor, interleukin 6), which may contribute to the molecular association between obesity and prostate cancer.
Source: www.europeanurology.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0Managing pancreatic neuroendocrine tumors - 6 month(s) ago
Pamela L. Kunz, MD, Yale University School of Medicine, New Haven, CT, talks on the challenging of managing endocrine tumors, including determination of treatment sequencing. Patients with low-grade or slow growing endocrine tumors tend to be treated with first-line somatostatin analogues, such as octreotide or lanreotide, with options expanding within the second-line treatment setting. Upcoming trials are utilizing comparator arms, including a Phase II trial (NCT05247905) comparing capecitabine plus temozolomide to lutetium Lu 177-dotatate in advanced pancreatic neuroendocrine tumors. Such trials enables comparison of active agents which has previously been lacking in the field. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 10Botulinum Toxin as a New Therapy Option for Voiding Disorders: Current State of the Art - 6 month(s) ago
Botulinum toxin is a presynaptic neuromuscular blocking agent inducing selective and reversible muscle weakness up to several months when injected intramuscularly in minute quantities. Different medical disciplines have discovered the toxin to treat mainly muscular hypercontraction. In urology, indications for botulinum-A toxin have been neurogenic detrusor overactivity, detrusor-sphincter dyssynergia, motor and sensory urge and, more recently, chronic prostatic pain.The available literature was reviewed using Medline Services.
Source: www.europeanurology.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0Belzutifan real-world vs clinical trial data: comparing efficacy and safety in VHL-associated tumors - 6 month(s) ago
Anusha Chidharla, MBBS, University of Kansas Medical Center, Kansas City, MO, compares the real-world data of belzutifan in VHL-associated tumors versus clinical trial data. The objective response rate (ORR) for associated renal cell cancer was 23%, lower than the clinical trial’s 49%, likely due to shorter follow-up duration (8 months vs. 21 months) and less frequent scans. Safety findings were similar, with common side effects being anemia and fatigue (65-70%). Belzutifan dose was decreased in 30% of our patients (vs. 15% in the clinical trial) due to poorer performance status (ECOG 1-2 vs. ECOG 0). These results highlight the importance of longer follow-up and more frequent scans to capture treatment responses accurately in the real-world setting. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer - 6 month(s) ago
Following two Delphi rounds and expert panel discussions, the European Association of Nuclear Medicine Focus 5 meeting reached consensus for key statements regarding the role of advanced imaging techniques in prostate cancer. It also contoured the place of theranostics in relation to the classical approach of conservative hormonal therapies or chemotherapies.
Source: www.europeanurology.comCategories: Latest Headlines, UrologyTweet
Congrats to our March IMPACT Award winners @AshwinUrol and Luke McGuinness! Their article “Management of Lymph Node–positive Penile Cancer: A Systematic Review” was the most influential work featured in our March 2024 issue! Full article here: https://t.co/QVpLGFZ0k0 #UroSoMe https://t.co/d0dXqWn6Ie